Promoter holding
64.27%
LI
Lifecell International Private Limited - Due diligence report
A 360° intelligence report on Lifecell: trust score, financial health, credit view, compliance, directors, growth and distress signals - gen…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Lifecell — 360° Intelligence Report
Generated from MCA filings & public records70/100
Trust Score
Moderate
Lifecell is assessed as Moderate with a Trust Score of 70/100. Lifecell is an active private limited indian non-government company incorporated in 2004, operating in the Life Sciences sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 08 Aug 2026 from the latest processed filings. Lifecell International Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
50/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
- Externally credit-rated (BBB-).
Charges position: 0 open (-) · 8 satisfied (442.38 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 6 | 48.0 cr |
| Indian Bank | 1 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
Compliance Score: 50/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 3 court forum(s).
- 2 auditor resignation(s) filed - latest: B S R & Co. LLP on 2019-11-26.
- Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
- 6 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SUMANTH SARANGAPANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUNNY SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUDHA VENKATARAMAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUMONA CHAKRABORTY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ABHAYA MAYUR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEEPAK ABHAYAKUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Svinod Kumar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 7 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
15 allotment(s) · 21 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Cellution Biologics Private Limited | Subsidiary Company | 74.00% |
| Lifecell Arabia Fz Llc | Subsidiary Company | 74.00% |
Key managerial personnel: SUMANTH SARANGAPANI (CEO) · ABHAYA MAYUR (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 70 · Distress 75
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Latest year revenue grew 1.42.
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Compliance score is weak (50/100).
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 1.68 Lakh.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence64/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment55/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view66/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events06 Jun 2025
Director appointed
Svinod Kumar (Cfo)
30 Oct 2024
Last AGM held
Annual general meeting
01 Aug 2024
Director ceased
DEEPAK ABHAYAKUMAR
30 Jun 2024
Director appointed
DEEPAK ABHAYAKUMAR (Director)
31 Mar 2024
Latest balance sheet
Filed with ROC
01 Sep 2023
Director appointed
SUMANTH SARANGAPANI (CEO)
01 Apr 2023
Director ceased
SVINOD KUMAR
27 Sep 2022
Director ceased
SUMONA CHAKRABORTY
22 Aug 2022
Securities allotted
17143 Equity Shares - 18.00 Lakh raised
Securities allotted
10646 Equity Shares - 22.36 Lakh raised
01 Jul 2022
Director appointed
SUDHA VENKATARAMAN (Company Secretary)
Director appointed
SUMONA CHAKRABORTY (Director)
03 Apr 2022
Director ceased
NATARAJAN RANGANATHAN
31 Mar 2022
Director ceased
ISHAAN KHANNA
22 Sep 2021
Securities allotted
100 Equity Shares - 42,671.00 raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Net worth is positive.
7 active director(s) / partner(s); board looks stable and experienced.
6 active GST registration(s) indicate ongoing business operations.
All 8 registered charge(s) stand satisfied - past borrowings repaid.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of BBB- from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 15 security allotment(s) - amounts available in the full report.
6 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Mumbai Oncocare Center | U74999MH2017PTC301138 | Borivali West, Maharashtra, India |
| Hufort Healthcare Private Limited | U24230MH2004PTC147961 | Mumbai, Maharashtra, India |
| Jai Ambey Emergency Services (I) Private Limited | U63030CT2015PTC001776 | Raipur, Chattisgarh, India |
| Tata Industries | U44003MH1945PLC004403 | Mumbai, Maharashtra, India |
| Ayushman Medical Diagnostics Pvt Ltd | U85195MP1990PTC006089 | Bhopal, Madhya Pradesh, India |
| Vhealth | U85100DL2008PTC184571 | New Delhi, Delhi, India |
| Pristyn Care | U85300HR2018PTC075460 | Dlf Qe, Haryana, India |
| Akumentis | U72900DL2010PLC206414 | Delhi, Delhi, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Lifecell before audits and certifications: compliance score 50/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Lifecell: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Lifecell - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Lifecell pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Lifecell - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Lifecell an active company?
Lifecell has MCA status “Active” with a compliance score of 50/100 (Moderate).
Is Lifecell financially healthy?
Lifecell has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.
Should I do business with Lifecell?
Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Lifecell?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 7 active director(s) are on record.
Does Lifecell have loans or charges against its assets?
No open charges - all 8 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Lifecell up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 50/100 (Moderate).
Is it risky to lend to Lifecell?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
